Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Mini Review Volume 5 Issue 6

Mass Chemoprophylaxis with Ivermectin against COVID-19 Pandemic: Review and Authors’ Perspective

Abdelmonem Awad Hegazy1,2*, Waheed M Shouman3, Raafat Awad Hegazy4 and Mohammed Saad Alghamdi5

1Professor, Department of Medical Biotechnology, Misr University for Science and Technology, College of Biotechnology (MUST), Egypt
2Professor, Department of Human Anatomy and Embryology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
3Professor, Department of Chest Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
4Professor, Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
5Consultant, Department of Family and Community Medicine, AlBaha Health Affairs, Ministry of Health, Saudi Arabia

*Corresponding Author: Abdelmonem Hegazy, Professor, Department of Medical Biotechnology, Misr University for Science and Technology, College of Biotechnology (MUST), Egypt.

Received: April 21, 2021; Published: May 14, 2021

Reprints View PDF Related Articles

×

Abstract

The current COVID-19 pandemic is a catastrophic health challenge widely spreading all over the world, caused by coronavirus “SARS-CoV-2” infections. It has been started for more than one year ago; and panic and fear are still dominated among people because of the ease with which infection spread among communities, as well as the high morbidity and mortality. Many preventive measures have been taken to prevent its spread, including physical body distancing, wearing face masks, etc. Unfortunately, the frequent mutations of the virus have made it a resistant to usual measures such as use of convalescent plasma from patients cured from infections. Several vaccines have been developed and administered as an urgent measure to combat the infection. Such vaccines could be not available for all countries especially that of low- and middle income. Moreover, the time for development of an approved vaccine in the normal situations that might reach about 10 - 15 years, is not available for vaccines used in the current pandemic. On the other hand, ivermectin, a drug approved by FDA as a broad-spectrum antiparasitic drug, has been clinically tried in prophylaxis of COVID-19 patients’ contacts and proved high efficacy. It is a safe and effective drug and has given tremendous results in protection against acquiring COVID-19 infection in all studies. Therefore, we suggest that ivermectin could be used for mass chemoprophylaxis without mentioned risks on populations. This measure might assist in combating the current COVID-19 outbreaks.

Keywords: COVID-19; Coronavirus Infection; Current Pandemic; Ivermectin; SARS-CoV-2

×

References

  1. Hegazy AA and Hegazy RA. “COVID- 19: Virology, pathogenesis and potential therapeutics”. Afro-Egyptian Journal of Infectious and Endemic Diseases 1 (2020): 93-99.
  2. “Coronavirus disease (COVID-19) pandemic” (2021).
  3. Prasad Singh J., et al. “Assessing the knowledge, attitude and practices of students regarding the COVID-19 pandemic”. Journal of Health Management 22 (2020): 281-290.
  4. Franchini M and Liumbruno GM. “Convalescent Plasma for the Treatment of Severe COVID-19”. Biologics 15 (2021): 31-38.
  5. Beusekom MV. “COVID meta-analysis: No benefit from convalescent plasma” (2021): 332021.
  6. Simonovich VA., et al. “A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia”. The New England Journal of Medicine 18 (2021): 619-629.
  7. Li L., et al. “Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID- 19: A randomized clinical trial”. JAMA 4 (2020): 460-470.
  8. Jung F., et al. “Herd immunity or suppression strategy to combat COVID-19”. Clinical Hemorheology and Microcirculation 75 (2020): 13-17.
  9. Izda V., et al. “COVID- 19: A review of therapeutic strategies and vaccine candidates”. Clinical Immunology 222 (2021): 108634.
  10. Sharma O., et al. “A review of the progress and challenges of developing a vaccine for COVID-19”. Frontiers in Immunology 14 (2020): 585354.
  11. https://www.who.int/news-room/q-a-detail/coronavirus-disease--vaccines
  12. Kobylinski KC., et al. “Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages”. American Journal of Tropical Medicine and Hygiene 85 (2011): 3-5.
  13. Wagstaff K. “Lab experiments show anti-parasitic drug, Ivermectin, eliminates SARS-CoV-2 in cells in 48 hours”. Monash Biomedicine Discovery Institute (2020).
  14. Prophylactic Ivermectin in COVID-19 Contacts; ClinicalTrials.gov (2020).
  15. Bryant A., et al. “Ivermectin for prevention and treatment of COVID-19 infection: A Systematic Review and Meta-analysis” (2021).
  16. Shouman WM., et al. “Use of ivermectin as a prophylactic option in asymptomatic family close contacts for patients with COVID-19” (2020).
  17. Elgazzar A., et al. “Efficacy and safety of ivermectin for Treatment and prophylaxis of covid-19 Pandemic”. Research Square (2020).
  18. Rajter JC., et al. “Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease”. Chest 159 (2021): 85-92.
  19. Kory P., et al. “Review of the Emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19”. American Journal of Therapeutics 1 (2021): 299-318.
  20. Shouman WM., et al. “Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: A randomized clinical trial”. Journal of Clinical and Diagnostic Research 15 (2021): 27-32.
  21. Yang SNY., et al. “The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer”. Antiviral Research 177 (2020): 104760.
  22. Lehrer S and Rheinstein PH. “Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2”. In Vivo 34 (2020): 3023-3026.
  23. Wagstaff KM., et al. “Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus”. Biochemical Journal 443 (2012): 851-856.
  24. Barrows NJ., et al. “A screen of FDA-approved drugs for inhibitors of Zika virus infection”. Cell Host and Microbe 20 (2016): 259-270.
  25. Tay MY., et al. “Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor ivermectin”. Antiviral Research 99 (2013): 301-306.
  26. DiNicolantonio JJ., et al. “Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19”. Open Heart 7 (2020): 001350.
  27. Zhang X., et al. “Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice”. Inflammation Research 57 (2008): 524-529.
  28. Ci X., et al. “Ivermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway”. Fundamental and Clinical Pharmacology 23 (2009): 449-455.
  29. “COVID-19 Treatment Guidelines” (2021).
  30. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials.
  31. López-Medina E., et al. “Effect of ivermectin on time to resolution of symptoms among adults with mild COVID- 19: A randomized clinical trial”. JAMA 13 (2021): 1426-1435.
  32. Speare R and Durrheim D. “Mass treatment with ivermectin: an underutilized public health strategy”. Bulletin of the World Health 559 (2004): 636.
  33. Ivermectin - WHO. “African Programme for Onchocerciasis Control (APOC)”.
  34. Hellwig MD and Maia A. “A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin”. International Journal of Antimicrobial Agents 57 (2021): 106248.
  35. Luis A., et al. “Ivermectin in COVID-19 Patients a Multicenter: Retrospective Study”. Journal of Infectious Diseases and Therapy 9 (2021): 1005.
  36. Mokhtari T., et al. “COVID-19 and multiorgan failure: A narrative review on potential mechanisms”. Journal of Molecular Histology 51 (2020): 613-628.
×

Citation

Citation: Hegazy., et al. “Mass Chemoprophylaxis with Ivermectin against COVID-19 Pandemic: Review and Authors’ Perspective”.Acta Scientific Medical Sciences 5.6 (2021): 47-51.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US





Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta-Publications

ff

© 2021 Acta Scientific, All rights reserved.